Barclays’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-325,106
| Closed | -$27.6M | – | 6740 |
|
|
2019
Q4 | $27.6M | Buy |
325,106
+150,577
| +86% | +$10M | 0.02% | 780 |
|
|
2019
Q3 | $8.73M | Buy |
174,529
+37,081
| +27% | +$1.48M | 0.01% | 1392 |
|
|
2019
Q2 | $5.01M | Buy |
137,448
+91,702
| +200% | +$2.99M | ﹤0.01% | 1862 |
|
|
2019
Q1 | $1.28M | Sell |
45,746
-15,631
| -25% | -$368K | ﹤0.01% | 3124 |
|
|
2018
Q4 | $1.18M | Sell |
61,377
-39,020
| -39% | -$908K | ﹤0.01% | 2952 |
|
|
2018
Q3 | $3M | Buy |
100,397
+51,675
| +106% | +$1.95M | ﹤0.01% | 2406 |
|
|
2018
Q2 | $1.79M | Buy |
48,722
+27,047
| +125% | +$879K | ﹤0.01% | 2679 |
|
|
2018
Q1 | $714K | Buy |
21,675
+3,704
| +21% | +$116K | ﹤0.01% | 3587 |
|
|
2017
Q4 | $491K | Sell |
17,971
-9,504
| -35% | -$293K | ﹤0.01% | 3847 |
|
|
2017
Q3 | $1.02M | Buy |
27,475
+8,090
| +42% | +$298K | ﹤0.01% | 2987 |
|
|
2017
Q2 | $737K | Sell |
19,385
-132,163
| -87% | -$5.89M | ﹤0.01% | 3152 |
|
|
2017
Q1 | $7.41M | Buy |
151,548
+115,336
| +319% | +$5.26M | 0.01% | 1071 |
|
|
2016
Q4 | $1.23M | Sell |
36,212
-73,395
| -67% | -$2.6M | ﹤0.01% | 2555 |
|
|
2016
Q3 | $4.14M | Buy |
109,607
+40,047
| +58% | +$1.51M | ﹤0.01% | 1436 |
|
|
2016
Q2 | $2.34M | Buy |
69,560
+27,602
| +66% | +$973K | ﹤0.01% | 1884 |
|
|
2016
Q1 | $1.3M | Sell |
41,958
-42,368
| -50% | -$1.38M | ﹤0.01% | 2311 |
|
|
2015
Q4 | $3.12M | Buy |
84,326
+9,605
| +13% | +$363K | ﹤0.01% | 1674 |
|
|
2015
Q3 | $2.77M | Buy |
74,721
+21,869
| +41% | +$768K | ﹤0.01% | 1844 |
|
|
2015
Q2 | $1.48M | Sell |
52,852
-13,442
| -20% | -$374K | ﹤0.01% | 2502 |
|
|
2015
Q1 | $1.86M | Buy |
66,294
+13,134
| +25% | +$369K | ﹤0.01% | 2394 |
|
|
2014
Q4 | $1.44M | Sell |
53,160
-56,164
| -51% | -$1.39M | ﹤0.01% | 2839 |
|
|
2014
Q3 | $2.4M | Buy |
109,324
+1,849
| +2% | +$47K | ﹤0.01% | 2508 |
|
|
2014
Q2 | $3.12M | Buy |
107,475
+56,973
| +113% | +$1.52M | ﹤0.01% | 2183 |
|
|
2014
Q1 | $1.41M | Sell |
50,502
-147,430
| -74% | -$4.88M | ﹤0.01% | 2885 |
|
|
2013
Q4 | $7.52M | Buy |
197,932
+113,053
| +133% | +$4.04M | 0.01% | 1479 |
|
|
2013
Q3 | $2.8M | Buy |
84,879
+9,970
| +13% | +$318K | ﹤0.01% | 2217 |
|
|
2013
Q2 | $2.31M | Buy |
+74,909
| New | +$2.51M | ﹤0.01% | 2394 |
|
Other funds holding MDCO
Barclays's MDCO Position: Q1 2020 in Review
Barclays sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 325,106 shares — an estimated $27.6M sold.
Barclays first reported a position in MDCO in Q2 2013 and held it in 27 quarters. The position peaked at $27.6M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Barclays reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Barclays sold 325,106 Medicines Co shares in Q1 2020, an estimated $27.6M.
- Barclays first reported a position in Medicines Co in Q2 2013 and held it in 27 quarters.
- Barclays's Medicines Co position peaked at $27.6M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.